Gilead Sciences to Present New HIV Research at AIDS 2026 Conference in Brazil
Gilead Sciences, Inc. is set to present its latest HIV research at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil. The company will showcase new scientific data from its HIV research and development programs, emphasizing its commitment to advancing HIV prevention, treatment, and cure research. Key highlights include long-term data from the PURPOSE 1 and PURPOSE 2 trials, which demonstrate the efficacy and safety of twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP). Additionally, Gilead will present results from the ISLEND-1 and ISLEND-2 Phase 3 trials, which explore a novel weekly HIV treatment regimen combining islatravir and lenacapavir. The conference will also feature discussions on expanding global access to lenacapavir, particularly in Latin America, and Gilead's ongoing partnerships with organizations like PEPFAR and the Global Fund. 
